Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-DEX versus VAD induction therapy for multiple myeloma
ISRCTN65684689Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 1996
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of idarubicin, dexamethasone, doxorubicin and vincristine in multiple myeloma (MM) and plasma cell neoplasm (2 arms), sponsored by Pfizer. Primary endpoint: Response rate. Started Oct 1996; status: completed.
02
Drugs
idarubicindexamethasonedoxorubicinvincristine
03
Conditions
multiple myeloma (MM)plasma cell neoplasm
Beyond the preview
Go deeper on ISRCTN65684689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65684689.